Altimmune (NASDAQ:ALT) Posts Quarterly Earnings Results, Beats Estimates By $0.02 EPS

Altimmune (NASDAQ:ALT) announced its quarterly earnings data on Tuesday. The company reported ($0.12) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.02, FiscalAI reports. Altimmune had a negative net margin of 214,860.98% and a negative return on equity of 42.57%.

Altimmune Price Performance

ALT stock opened at $2.93 on Thursday. The business has a 50 day moving average price of $2.90 and a 200 day moving average price of $3.42. The company has a quick ratio of 29.56, a current ratio of 29.56 and a debt-to-equity ratio of 0.12. The stock has a market cap of $569.80 million, a price-to-earnings ratio of -3.15 and a beta of 0.27. Altimmune has a fifty-two week low of $2.56 and a fifty-two week high of $6.44.

Institutional Trading of Altimmune

Several institutional investors have recently modified their holdings of the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in shares of Altimmune by 4.8% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 48,901 shares of the company’s stock valued at $247,000 after buying an additional 2,241 shares during the last quarter. Geneos Wealth Management Inc. acquired a new position in Altimmune during the first quarter worth approximately $50,000. Envestnet Asset Management Inc. lifted its stake in Altimmune by 48.0% in the second quarter. Envestnet Asset Management Inc. now owns 32,908 shares of the company’s stock valued at $127,000 after buying an additional 10,671 shares during the last quarter. Creative Planning grew its position in shares of Altimmune by 30.2% during the second quarter. Creative Planning now owns 41,164 shares of the company’s stock worth $159,000 after acquiring an additional 9,558 shares during the last quarter. Finally, Rhumbline Advisers increased its holdings in shares of Altimmune by 7.0% in the 2nd quarter. Rhumbline Advisers now owns 113,981 shares of the company’s stock valued at $441,000 after acquiring an additional 7,462 shares during the period. Hedge funds and other institutional investors own 78.05% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Altimmune in a research report on Wednesday, June 24th. Wall Street Zen upgraded Altimmune from a “strong sell” rating to a “sell” rating in a report on Saturday, June 27th. Citigroup reiterated a “market outperform” rating on shares of Altimmune in a research note on Tuesday, June 2nd. Leerink Partners assumed coverage on Altimmune in a research report on Monday, June 22nd. They set an “outperform” rating and a $10.00 price objective for the company. Finally, HC Wainwright restated a “buy” rating on shares of Altimmune in a research note on Tuesday, July 28th. Seven research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $14.33.

Altimmune Company Profile

Altimmune, Inc is a clinical-stage biopharmaceutical company headquartered in Gaithersburg, Maryland, dedicated to the development of vaccines and immunotherapeutics. The company leverages proprietary technology platforms to create intranasal vaccine candidates and novel therapies targeting liver diseases and metabolic disorders. Altimmune’s approach emphasizes the stimulation of both systemic and mucosal immune responses to address unmet medical needs in infectious and chronic conditions.

Among its lead programs, NasoVAX is an investigational intranasal influenza vaccine designed to provide broad, long-lasting protection through a single, non-invasive dose.